Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

NCT00026182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

NIH

Sponsor class

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma

Interventions

BIOLOGICAL: rituximab
BIOLOGICAL: recombinant interleukin-12
OTHER: laboratory biomarker analysis
OTHER: questionnaire administration
PROCEDURE: quality-of-life assessment

Sponsor

National Cancer Institute (NCI)